Pressure BioSciences, Inc. to Discuss Second Quarter 2022 Financial Results and Provide Business Update

August 16, 2022 4:10 PM

Conference Call Scheduled for Thursday August 18 at 4:30pm ETSOUTH EASTON, MA / ACCESSWIRE / August 16, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Second Quarter 2022 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link...

Read more

enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations

August 16, 2022 8:05 AM

IRVINE, CA / ACCESSWIRE / August 16, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the appointment of Kevin Belteau as Vice President of Clinical Operations. Mr. Belteau joins enVVeno Medical following a twenty-three-year career in clinical operations at Medtronic.Mr. Belteau joined Medtronic as a field engineer upon...

Read more

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

August 15, 2022 4:05 PM

Dermata completes a $5.0 million private placement financing in April 2022DMT310 Phase 2 rosacea trial topline results expected in the second half of 2022SAN DIEGO, CA / ACCESSWIRE / August 15, 2022 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today highlighted recent corporate progress and reported...

Read more

Ichor Life Sciences Invests $1.5 Million in MitoChem Therapeutics for Ocular Aging Disease Research

August 15, 2022 3:00 PM

LAFAYETTE, NY / ACCESSWIRE / August 15, 2022 / Ichor Life Sciences, a preclinical contract research organization, today announced a $1.5 million investment in MitoChem Therapeutics. Based in Charleston, South Carolina, MitoChem Therapeutics develops treatments to address the effects of mitochondrial dysfunction-a hallmark of aging-in neurodegenerative diseases.MitoChem Therapeutics and Ichor Life Sciences will work together to advance the...

Read more

Biovica invites to market update on 18 August 15.00 - Bringing DiviTum(R)TKa to US patients

August 15, 2022 9:10 AM

UPPSALA, SE / ACCESSWIRE / August 15, 2022 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II)Biovica, active in cancer diagnostics, is hosting a market update due DiviTum®TKa's US market approval received on July 29 from the US Food and Drug Administration (FDA).At the update on Thursday 18 August 15.00-16.00 CET, CEO Anders Rylander will give a short introduction. Joakim Arwidsson, VP RA/QA, about the 510(k) clearance, Henrik...

Read more

EV Biologics Launches Excyte with $100 million Valuation

August 15, 2022 9:00 AM

TAMPA, FL / ACCESSWIRE / August 15, 2022 / EV Biologics Corp, OTC Pink: YECO, today announced that it has launched Excyte, Inc., a wholly owned subsidiary, with $100 Million valuation.Excyte has already raised $500,000 of its $2.5 million initial capitalization goal. This funding will initially provide scale-down biomanufacturing process development and important bioanalytical data to advance EV Biologics' ongoing nanotherapeutic...

Read more

Vaso Corporation Announces Financial Results for Second Quarter 2022

August 15, 2022 9:00 AM

Company reports net income of $1.5 million on significant revenue growthPLAINVIEW, NY / ACCESSWIRE / August 15, 2022 / Vaso Corporation ("Vaso") (OTC PINK:VASO) today reported its operating results for the three months ended June 30, 2022."For the second quarter of 2022, the Company recorded a total revenue of $19.5 million, representing a 21% increase year-over-year. As a result, net income improved substantially, to $1.5 million from a net...

Read more

Petros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022

August 15, 2022 8:00 AM

NEW YORK, NY / ACCESSWIRE / August 15, 2022 / Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announced financial results for the second quarter ended June 30, 2022.Highlights include:Reported Net Sales for Q2 of $4.2 millionAchieved first positive quarter of Adjusted EBITDA over $200,000Announced positive results of over-the-counter (OTC) label comprehension...

Read more

Black Bird Biotech Management Affirms Long-Term Commitment, Exchanges One-Third, over 120 Million, of Outstanding Common Shares for Preferred Shares

August 15, 2022 8:00 AM

FLOWER MOUND, TX / ACCESSWIRE / August 15, 2022 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer and distributor of plant-based MiteXstreamTM biopesticide, announced that the members of its Board of Directors have agreed to exchange a total of nearly 124 million shares, or approximately 36%, of the Company's outstanding common stock for shares of a new Series A Preferred Stock. All of the transactions are expected to be completed by...

Read more

Hemogenyx Pharmaceuticals PLC Announces Approval and Issuance of Antibody Patent

August 15, 2022 2:00 AM

Approval and Issuance of Chinese Bi-specific Antibody PatentLONDON, UK / ACCESSWIRE / August 15, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that China National Intellectual Property Administration has issued a Notification to Grant Patent Right for the patent application entitled METHOD OF ELIMINATING HEMATOPOIETIC STEM...

Read more

Core One Labs' Subsidiaries Successfully Produce Psilocin Precursor for Production to Psilocybin

August 12, 2022 7:55 PM

VANCOUVER, BC / ACCESSWIRE / August 12, 2022 / Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6, WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce that scientists at its wholly-owned subsidiary Awakened Biosciences Inc. ("Awakened") have successfully produced a precursor that can be efficiently converted into psilocin, the psychoactive ingredient of psilocybin, with further conversion into commercially viable...

Read more

Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results

August 12, 2022 4:30 PM

Phase 3 ARDS drug study in hospitalized Covid-19 patients expandedCompany reaffirms guidance on completion of Phase 2b dermatology drug studyTORONTO, ON / ACCESSWIRE / August 12, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and nine months ended June 30, 2022 and provided an update on its business.During the...

Read more

Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

August 12, 2022 8:00 AM

Second quarter marked by deal to in-license DNase-based oncology platform which expands pipeline with well-defined and accelerated path to clinicAdvancing lead DNase program towards Phase 1 study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumorsEnded the quarter with $14.9 million of cash to fund operations and drive expanded pipeline development forwardFRAMINGHAM, MA / ACCESSWIRE / August 12, 2022...

Read more

Ensysce Biosciences Provides Business Update and Reports Second Quarter 2022 Financial Results

August 11, 2022 4:10 PM

Corporate Update Call to be Held Wednesday, August 17, 2022SAN DIEGO, CA / ACCESSWIRE / August 11, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, today reported financial results for the second quarter 2022.Dr. Lynn Kirkpatrick, Chief Executive...

Read more

Lexaria Discusses Valuation Metrics for Biotech Industry

August 11, 2022 9:15 AM

Third Party Analysis for Biotech and Pharma IndustriesKELOWNA, BC / ACCESSWIRE / August 11, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following information to its stakeholders as an aid to conveniently researching and understanding various non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical...

Read more

NovAccess Global Announces Uplisting to OTCQB

August 10, 2022 9:00 AM

CLEVELAND, OH / ACCESSWIRE / August 10, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that the trading of its common shares has been upgraded to the OTC Markets Group's OTCQB® platform from the OTC Pink Market. The Company's ticker symbol remains the same.The OTCQB listing required the completion and submission of financial reporting with the...

Read more

Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension

August 10, 2022 8:15 AM

Significant Milestone Achieved in Commercial Product Development ProgramAbbreviated 505(b)(2) Strategy Confirmed as an Appropriate NDA PathwayKELOWNA, BC / ACCESSWIRE / August 10, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that it has received a positive full written response from the Food and Drug Administration ("FDA") from its...

Read more

Hemogenyx Pharmaceuticals PLC Announces Appointment of Medical Director

August 10, 2022 2:00 AM

One of America's Top Bone Marrow Transplant and Oncology Doctors Joins Hemogenyx Pharmaceuticals as Medical DirectorLONDON, UK / ACCESSWIRE / August 10, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces the appointment of Dr Koen van Besien as Medical Director.Dr van Besien is Chief of the Division of Hematology and head of the Wesley Center for...

Read more

Biolab Strengthens Its Presence With the Purchase of Exzell Pharma

August 9, 2022 12:10 PM

MARKHAM, ON / ACCESSWIRE / August 9, 2022 / Biolab Pharma announced today the acquisition of the Canadian healthcare business, Exzell Pharma, based in Markham, Ontario. The deal represents another significant step to strengthen its international presence by acquiring a sales and marketing infrastructure as well as important established brands such as Swiss Naturals, Salinex, Esoph, and Myoflex.Biolab Pharma is a subsidiary of Biolab...

Read more

Black Bird Biotech Opens Grizzly Creek Naturals CBD Affiliate Sales Sign-up Portal Ahead of Sales Program Launch

August 9, 2022 8:55 AM

FLOWER MOUND, TX / ACCESSWIRE / August 9, 2022 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer and distributor of plant-based MiteXstreamTM biopesticide, announced the opening of a Sign-up Portal for its Affiliate Sales Program for its Grizzly Creek NaturalsTM CBD product line. Future Grizzly Creek NaturalsTM Affiliate Sales Reps can sign up at GrizzlyCreekAffiliates.com. The Company has scheduled the program launch for September 7,...

Read more